Evaluating Patients With Abnormal Levels of Gastric Acid

• Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00001240
• Collaborator: (none)
• Location: 1
• Duration (Months): 180

Study Details

Study Description

Brief Summary

This study is used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities in the secretion of gastric acid. The level of gastric acid is measured by analyzing the gastric juices of each individual patient. The gastric acid sample is obtained by a procedure known as nasogastric suctioning, where a thin plastic tube is passed from the nose to the stomach.

Depending on the patient's present condition further diagnostic testing may be required to achieve a diagnosis.

Condition or Disease	Intervention/Treatment	Phase
Achlorhydria; Gastrinoma; Zollinger Ellison Syndrome

Detailed Description

This study is an omnibus protocol used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities of gastric acid secretion. Gastric acid secretion is measured by means of analysis of gastric juices obtained by nasogastric suction. Other clinically indicated diagnostic procedures are performed depending on the patient's clinical state in order to reach a diagnosis.

Study Design

• Study Type: Observational
• Official Title: Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion
• Study Start Date: Jan 1, 1989
• Study Completion Date: Jan 1, 2004

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Eligibility criteria not identified in the protocol.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Bethesda	Maryland	United States	20892

Sponsors and Collaborators

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

• Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):1026-33.
• McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):939-44.
• Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT. Famotidine in the therapy of gastric hypersecretory states. Am J Med. 1986 Oct 24;81(4B):49-59.

• ClinicalTrials.gov Identifier: NCT00001240
• Other Study ID Numbers: 890005; 89-DK-0005
• First Posted: Nov 4, 1999
• Last Update Posted: Mar 5, 2008
• Last Verified: Jan 1, 2004

• Keywords provided by , ,: Stomach; Hypersecretion; Hyposecretion; Gastrinoma; Zollinger-Ellison Syndrome
• Additional relevant MeSH terms: Gastrinoma; Zollinger-Ellison Syndrome; Achlorhydria

Study Results

No Results Posted as of Mar 5, 2008